ATS 2020 Advance Program

exciting advances to replace surgical interventions with minimally-invasive therapies. Chairing: C. Broaddus, MD, San Francisco, CA C.R. Lamb, MD, Burlington, MA N. Rahman, BM BCH, MSc, Oxford, United Kingdom 2:15 Surgical Role in Diagnosis and Management of Pleural Diseases K. Yasufuku, MD, Toronto, Canada 2:35 Advances in Pleural Cytology Reducing Need of Surgical Biopsies S.M. Chai, MBBS, Perth, Australia 2:50 Advances in Interventional Radiology Reducing Need of Surgical Biopsies N. Maskell, DM , Bristol, United Kingdom 3:05 Advances Non-Surgical Management of Spontaneous Pneumothorax E. Ball, MD, Hobart, Australia 3:20 Advances in Non-Surgical Management of Pleural Infection Y.C.G. Lee, MBChB, PhD, Perth, Australia 3:40 Advances in Non-Surgical Management of Malignant Pleural Effusion D.J. Feller-Kopman, MD, Baltimore, MD 4:00 Radical Surgery for Mesothelioma: A Foregone Conclusion? J. Edwards, MB ChB, PhD, Sheffield, United Kingdom CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE B83 EARLY DETECTION AND DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS Assembly on Clinical Problems 2:15 p.m. - 4:15 p.m. Target Audience Clinical and translational researchers interested in methods of early detection and diagnosis of IPF; clinicians who care for patients with interstitial lung disease (ILD). Objectives At the conclusion of this session, the participant will be able to: • improve understanding of the potential clinical impacts of early diagnosis of IPF on patient management, therapy, and outcomes; • learn new findings about interstitial lung abnormalities (ILAs), their relationship to patient mortality, and ongoing research on the relationship between ILAs and IPF and identifying ILAs in high-risk patient populations; • learn new findings about methods with potential for early diagnosis of usual interstitial pneumonitis (UIP)/IPF, including recent studies on genomic classifiers and ongoing research on novel in vivo endobronchial optical microscopy imaging methods. In this symposium, we will discuss the clinical significance of early detection and diagnosis of idiopathic pulmonary fibrosis (IPF), including the recent data on anti-fibrotic therapy in IPF patients with less severe disease resulting in lung function preservation. We will discuss methods for early IPF diagnosis, including detection of interstitial lung abnormalities (ILA) on HRCT in high-risk patient populations. We will also discuss the use of genomic classifiers and novel in vivo endobronchial optical microscopy imaging for early diagnosis of usual interstitial pneumonitis (UIP)/IPF. Chairing: L.P. Hariri, BS, MD, PhD, Boston, MA G.M. Hunninghake, MD, MPH, Boston, MA A. Podolanczuk, MD, New York, NY 2:15 Early Diagnosis of IPF and Impacts on Clinical Management, Therapy and Patient Outcomes L. Richeldi, PhD, MD, Rome, Italy 2:35 Moving the Field of Early Pulmonary Fibrosis Detection to Clinical Practice G.M. Hunninghake, MD, MPH, Boston, MA 3:00 Subclinical Interstitial Lung Disease: Experience from the Multi-Ethnic Study of Atherosclerosis A. Podolanczuk, MD, New York, NY 3:25 When and Why Interstitial Lung Abnormalities are Clinically Important? R.K. Putman, MD, MPH, Boston, MA ATS 2020 • Philadelphia, PA 88 MONDAY • MAY 18